reports
- Christophe-Raphaël Ganet
Ipsen : Feedback from Q1 2024 webcast
>Slower growth over the coming quarters? - Highlights from yesterday’s meeting:1/ Q1 was a good quarter, but growth in Q1 (+13% cc) seems unlikely to be extrapolated: i/ new generic versions of Somatuline are set to reach Europe and North America in H2 2024/early 2025, ii/ Cabometyx benefited from a cut-off effect, resulting in a favourable cumulative impact of =€ 20me in Q1.Management remains optimistic about Dysport (market share gains and indication exten...
- Christophe-Raphaël Ganet
Ipsen : Feedback webcast T1 2024
>Moindre croissance sur les prochains trimestres ? - De la réunion d’hier, nous retenons que :1/ T1 a été bon mais la croissance du T1 (+13% à tcc.) ne semble pas extrapolable : i/ de nouveaux génériques de Somatuline devraient arriver en Europe et en Amérique du Nord au S2 2024/début 2025, ii/ Cabometyx a bénéficié d’un effet de cut-off, soit un impact favorable cumulé de =20 M€e, au T1.La Direction s’est montrée toujours optimiste pour Dysport (prise de Pd...
- Chaima Ferrandon
- Sven Edelfelt
HEIA HEINEKEN NV
AI AIR LIQUIDE SA
IPN IPSEN SA
DB1 DEUTSCHE BOERSE AG
KNEBV KONE OYJ CLASS B
RNO RENAULT SA
KPN ROYAL KPN NV
COV COVIVIO SA
ROG ROCHE HOLDING LTD
ORA ORANGE SA
SSAB A SSAB AB CLASS A
FGR EIFFAGE SA
KER KERING SA
RAND RANDSTAD NV
ENI ENI S.P.A.
ASM ASM INTERNATIONAL N.V.
ASSA B ASSA ABLOY AB CLASS B
INGA ING GROEP NV
AD KONINKLIJKE AHOLD DELHAIZE N.V.
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
EPI A EPIROC AB
- Chaima Ferrandon
- Sven Edelfelt
AI AIR LIQUIDE SA
IPN IPSEN SA
DB1 DEUTSCHE BOERSE AG
KNEBV KONE OYJ CLASS B
RNO RENAULT SA
KPN ROYAL KPN NV
COV COVIVIO SA
ROG ROCHE HOLDING LTD
ORA ORANGE SA
SSAB A SSAB AB CLASS A
FGR EIFFAGE SA
KER KERING SA
RAND RANDSTAD NV
ENI ENI S.P.A.
ASM ASM INTERNATIONAL N.V.
ASSA B ASSA ABLOY AB CLASS B
INGA ING GROEP NV
AD KONINKLIJKE AHOLD DELHAIZE N.V.
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
EPI A EPIROC AB
- Christophe-Raphaël Ganet
Ipsen : Q1 2024 sales: broadly above consensus forecasts
>Q1 2024 sales: +13.3%: a good organic level - Q1 2024 sales were € 822.4m, +10.9% (+13.3% cc.) with sales in oncology up +7.5% cc, rare diseases +69% cc (although with the entry into the scope of consolidation of Sohonos) and neuroscience at +19.6% cc.Forex had an impact of close to -2.5% in Q1.The group reaffirmed its guidance (growth of 6% cc and an operating margin of around 30%).The main franchises are solid - New products faring well - §sep...
- Christophe-Raphaël Ganet
Ipsen : CA T1 2024 : plutôt supérieur aux attentes du consensus
>CA T1 2024 : +13,3% : bon niveau d’organique - Le CA T1 2024 atteint 822,4 M€, +10,9% (+13,3% à tcc.) avec un CA Oncologie, à +7,5% à tcc., Maladies Rares à +69% à tcc. (avec toutefois l’entrée dans le périmètre de Sohonos) et Neurosciences à 19,6% à tcc..Les effets devises ont un impact de près de -2,5% sur ce T1.Le groupe réaffirme ses guidances (croissance de 6% à tcc. et MOP. d’environ 30%).Les grandes franchises sont solides – Les nouveaux...
- Jan Frederik Slijkerman
- Jeroen van den Broek
- Jesse Norcross
- Nadège Tillier
- Timothy Rahill
- ING Helpdesk
Benelux Morning Notes
ASM International: 1Q24 results - better on all fronts. Heineken: Uphill from here. KPN: 1Q24 in line, guidance slightly increased on Youfone acquisition. Melexis: 1Q24 results in line a relief. Universal Music Group: Spotify 1Q24 Results and guidance beat on margins. Vopak: Good progress to start the year. Wereldhave: 1Q24 LFL slows sharply
- Konrad Zomer
KPN : Q1 results marginally ahead of consensus and FY guidance raised
>Q1 results show positive momentum – FY guidance raised - In its Q1 earnings release, KPN reported group revenues and adjusted EBITDAaL of €1,377m (+3.3%) and €605m (+3.6%) respectively. This compares with consensus estimates of €1,376m (we at €1,377m) and € 602m (we at €599m) respectively. So results are marginally ahead of consensus. Group capex came in at €302m (css: € 301m) and FCF at €154m (-5.8% yoy with consensus at €173m and we at € 185m, the difference is ex...
TotalEnergies et Vanguard Renewables, société du portefeuille de l’act...
PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News: TotalEnergies (Paris:TTE) (LSE:TTE) (NYSE:TTE), compagnie multi-énergies intégrée mondiale, et Vanguard Renewables, société détenue en portefeuille par un fonds géré par BlackRock et leader américain de la production de biométhane à partir de déchets organiques, ont conclu un accord pour la création d’une coentreprise détenue à 50/50 en vue de développer, construire et opérer des projets de biométhane implantés dans des exploitations agricoles aux États-Unis. La signature de l’accord s’est tenue à New York le 12 avril 2024 en présence de Pat...
République du Congo : TotalEnergies accroît sa participation dans le c...
PARIS--(BUSINESS WIRE)-- Regulatory News: TotalEnergies (Paris:TTE) (LSE:TTE) (NYSE:TTE) annonce la signature par sa filiale TotalEnergies EP Congo, détenue à 85 %, d’un accord avec Trident Energy portant simultanément sur l’acquisition auprès de Trident Energy d’une participation supplémentaire de 10 % dans le permis Moho et sur la vente à Trident Energy d’une participation de 53,5 % dans les permis Nkossa et Nsoko II. Moho est un champ offshore en eaux profondes situé à 80 kilomètres au large de Pointe-Noire, et opéré par TotalEnergies EP Congo. La production a significativement augmenté...
- Anthony Dick
- Michael Foundoukidis
Renault : The best is yet to come
>Q1 sales a shade above expectations thanks to financial services - Yesterday, Renault published Q1 2024 sales that came in slightly above expectations at € 11.7bn (+2% vs the consensus at € 11.5bn), largely driven by the financial services business (+28%, 11% above estimates) whilst the Autos business was in line (€ 10.4bn) despite a more negative volumes contribution (-4.6 vs -2.8 points), slightly less robust pricing than expected (+4.1 vs +5.0 points) and thanks ...
- Anthony Dick
- Michael Foundoukidis
Renault : Le meilleur reste à venir
>CA T1 légèrement supérieur aux attentes grâce aux services financiers - Renault a publié, hier, un CA T1 2024 légèrement supérieur aux attentes à 11.7 Md€ (+2% vs css à 11.5 Md€), essentiellement tiré par les services financiers (+28%, 11% au-dessus des attentes) alors que l’Automobile était en ligne (10.4 Md€) malgré des volumes plus négatifs (-4.6 vs -2.8 pt), un pricing légèrement moins robuste qu’attendu (+4.1 vs +5.0 pt) et grâce aux partenaires (+2.4 vs +0.3 p...
Q1 2024 results: KPN delivers solid start to the year
Q1 2024 results: KPN delivers solid start to the year Continued Group service revenue growth (+3.6% y-on-y), mainly driven by Consumer (+4.5%) and Business (+3.2%)Ongoing positive net adds in Consumer postpaid +30k and broadband +13k, of which 8k related to Kabeltex acquisitionExpanded fiber footprint with +130k HP in Q1 2024 (+159k HP including Glaspoort)Adj. EBITDA AL of € 605m (+3.6% y-on-y), quarterly FCF generation impacted by intra-year phasingACM unconditionally approved Youfone acquisition, transaction closed on 4 AprilFull year 2024 outlook raised to ~€ 2,500m adjusted EBITDA AL an...
Ipsen delivers strong sales in the first quarter of 2024, driven by gr...
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance PARIS, FRANCE, 24 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024. Q1 2024 Q1 2023 % change €m €m ActualCER1Growth platforms2509.7452.012.8%16.2%New medicines345.514.3n/an/aSomatuline®257.8263.2-2.0%-1.3%Other9.512.4-23.8%-20.5%Total Sales822.4741.910.9%13.3% Highlights Total-sales growth of 13.3% at CER1, or 10.9% as reported, driven by t...
Ipsen enregistre une solide croissance de ses ventes au premier trimes...
Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l'exercice 2024 PARIS, FRANCE, 24 avril 2024 - Ipsen (Euronext : IPN ; ADR : IPSEY), groupe biopharmaceutique mondial de spécialité, publie aujourd’hui son chiffre d’affaires pour le premier trimestre 2024. Q1 2024 Q1 2023 % change €m €m Réalisé TTC1Plateforme de croissance2 509,7452,012,8%16,2%Nouveaux médicaments3 45,514,3n/an/aSomatuline® 257,8263,2-2,0%-1,3%Autres 9,512,4-23,8%-20,5%Chiffre d’affaires Groupe 822,4741,910.9%13.3% Faits marquants Croissance des ventes de...
- Kris Kippers
KPN - Solid Q1 and guidance includes Youfone M&A
KPN's Q1 was rock solid and did not contain surprises nor on top line, nor on cash generationThe recently approved transaction of Youfone results in a tweaking of its 2024 guidance and once more it slightly raised its FCF guidance by EUR 10mSolid numbers for the Dutch market leader, Hold maintained
TechnipFMC Declares Quarterly Dividend
NEWCASTLE & HOUSTON--(BUSINESS WIRE)-- TechnipFMC plc (NYSE: FTI) today announced that its Board of Directors has authorized and declared a quarterly cash dividend of $0.05 per share, payable on June 5, 2024 to shareholders of record as of the close of business on the New York Stock Exchange on May 21, 2024. The ex-dividend date is May 20, 2024. Important Information for Investors and Securityholders Forward-Looking Statement This release contains "forward-looking statements" regarding our future dividend payment obligations as defined in Section 27A of the United States Securities Act o...
Amundi: Ordinary general meeting of shareholders, 24th May 2024
Amundi: Ordinary general meeting of shareholders, 24th May 2024 Ordinary general meeting of shareholders, 24th May 2024 Arrangements for making preparatory documents available and consulting them Paris, 23 April 2024 The Ordinary General Meeting of shareholders of Amundi will be held at 10. a.m. Paris time on Friday, 24th May 2024 at the company’s head office at 91-93, boulevard Pasteur, 75015 PARIS. The notice of meeting, including the agenda and the draft resolutions, was published in the Bulletin des Annonces Légales et Obligatoires (BALO, French gazette for compulsory legal announce...
- Ahmed Ben Salem
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.